A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...
Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...
The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.
James analyst Dane Leone maintained a Strong Buy rating and a $19.00 price target on Ocular Therapeutix (NASDAQ:OCUL), aligning with the broader analyst consensus. According to InvestingPro data, ...
Diabetic vitreous hemorrhage is linked to neuropathologic changes in specific brain regions, as identified by voxel-based ...
BEDFORD, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular”), a biopharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback